High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production.
Ashlan J Kunz CoyneAmer El GhaliKristen LucasPaige WituckiNicholas ReboldDana J HolgerMichael P VeveMichael Joseph RybakPublished in: Open forum infectious diseases (2023)
Among patients with bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC production, these data demonstrate similar risk of 30-day mortality for high-dose cefepime or a carbapenem as definitive β-lactam therapy.
Keyphrases
- high dose
- gram negative
- multidrug resistant
- low dose
- stem cell transplantation
- klebsiella pneumoniae
- high intensity
- escherichia coli
- electronic health record
- acinetobacter baumannii
- cardiovascular events
- cardiovascular disease
- type diabetes
- big data
- locally advanced
- coronary artery disease
- risk factors
- drug resistant
- bone marrow
- deep learning
- stem cells
- data analysis
- cell therapy